397 related articles for article (PubMed ID: 31092758)
41. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
[TBL] [Abstract][Full Text] [Related]
42. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Llovet JM; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
Cardiovasc Intervent Radiol; 2022 Apr; 45(4):405-412. PubMed ID: 35119481
[TBL] [Abstract][Full Text] [Related]
43. EGFR activation limits the response of liver cancer to lenvatinib.
Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
[TBL] [Abstract][Full Text] [Related]
44. Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients.
Lin PT; Teng W; Jeng WJ; Lin CY; Lin SM; Sheen IS
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):213-219. PubMed ID: 33177386
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.
Ikeda S; Kudo M; Izumi N; Kobayashi M; Azuma M; Meier G; Pan J; Ishii M; Kaneko S
Value Health Reg Issues; 2021 May; 24():82-89. PubMed ID: 33524900
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
[TBL] [Abstract][Full Text] [Related]
47. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
48. A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
Hatanaka T; Kakizaki S; Nagashima T; Ueno T; Namikawa M; Tojima H; Takizawa D; Naganuma A; Arai H; Sato K; Harimoto N; Shirabe K; Uraoka T
Acta Gastroenterol Belg; 2021; 84(1):65-72. PubMed ID: 33639695
[TBL] [Abstract][Full Text] [Related]
49. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
[TBL] [Abstract][Full Text] [Related]
50. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
Teng Y; Ding X; Li W; Sun W; Chen J
Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
[No Abstract] [Full Text] [Related]
51. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
Bai Y; Hu X; Ren Z; Hisai T; Yusa W; Weng L; Shiba S; Takase T
Future Oncol; 2022 Jul; 18(22):2413-2424. PubMed ID: 35674480
[TBL] [Abstract][Full Text] [Related]
52. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
53. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
54. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
Meyers BM; Vogel A; Marotta P; Kavan P; Kamboj L; Pan J; Geadah M; Trueman D; Sabapathy S
Can J Gastroenterol Hepatol; 2021; 2021():8811018. PubMed ID: 33681090
[TBL] [Abstract][Full Text] [Related]
55. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor-platelet interactions.
Tanaka H; Horioka K; Hasebe T; Sawada K; Nakajima S; Konishi H; Isozaki S; Goto M; Fujii Y; Kamikokura Y; Ogawa K; Nishikawa Y
Int J Cancer; 2022 May; 150(10):1640-1653. PubMed ID: 34935134
[TBL] [Abstract][Full Text] [Related]
56. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
57. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.
Zhu J; Fang P; Wang C; Gu M; Pan B; Guo W; Yang X; Wang B
Cancer Med; 2021 Nov; 10(22):7977-7987. PubMed ID: 34605616
[TBL] [Abstract][Full Text] [Related]
58. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET.
Zschäbitz S; Grüllich C
Recent Results Cancer Res; 2018; 211():187-198. PubMed ID: 30069768
[TBL] [Abstract][Full Text] [Related]
59. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
60. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.
Une N; Takano-Kasuya M; Kitamura N; Ohta M; Inose T; Kato C; Nishimura R; Tada H; Miyagi S; Ishida T; Unno M; Kamei T; Gonda K
Med Oncol; 2021 Apr; 38(6):60. PubMed ID: 33881631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
